Aristotle University of Thessaloniki, AHEPA University Hospital, First Propedeutic Department of Internal Medicine, Thessaloniki, Greece.
Expert Opin Ther Targets. 2011 Apr;15(4):401-20. doi: 10.1517/14728222.2011.553609. Epub 2011 Jan 25.
Several peptides are involved in the regulation of food intake and energy expenditure, among which are leptin, adiponectin, ghrelin and neuropeptide Y (NPY). These peptides may be implicated in the obesity seen in the majority of patients with type 2 diabetes mellitus (T2DM).
The present review considers: i) the role of leptin, adiponectin, ghrelin and NPY in patients with T2DM, and, ii) the effect of insulin as well as oral hypoglycemic, antihypertensive, hypolipidemic, antiobesity and antiplatelet agents on these peptides in patients with T2DM.
Patients with T2DM have either lower or similar leptin levels, decreased adiponectin and ghrelin levels, and increased NPY circulating levels compared with nondiabetic controls. Treatment with insulin, oral hypoglycemic, antihypertensive, hypolipidemic, antiobesity and antiplatelet drugs may influence the levels of these peptides. It is not widely appreciated that several drugs commonly administered to patients with T2DM can influence adipokine levels. The clinical relevance of these effects needs to be evaluated.
有几种肽参与了食物摄入和能量消耗的调节，其中包括瘦素、脂联素、胃饥饿素和神经肽 Y（NPY）。这些肽可能与大多数 2 型糖尿病（T2DM）患者的肥胖有关。
本综述考虑了：i）瘦素、脂联素、胃饥饿素和 NPY 在 T2DM 患者中的作用，以及 ii）胰岛素以及口服降糖药、降压药、降脂药、减肥药和抗血小板药对 T2DM 患者这些肽的影响。
与非糖尿病对照相比，T2DM 患者的瘦素水平要么更低，要么相似，脂联素和胃饥饿素水平降低，NPY 循环水平升高。胰岛素、口服降糖药、降压药、降脂药、减肥药和抗血小板药的治疗可能会影响这些肽的水平。人们并没有广泛认识到，几种常用于治疗 T2DM 患者的药物会影响脂肪细胞因子的水平。需要评估这些影响的临床意义。
